INTRODUCTION: BILE ACIDS, FAT ABSORPTION, AND THE ENTEROHEPATIC CIRCULATION
Bile acids (BAs) are detergent molecules 1 that are synthesized in the liver and are responsible for solubilization of fatty acids and monoglycerides (the lipolysis products of triglycerides), facilitating digestion and lipid absorption in the small intestine. The different BA molecules are differentiated by hydroxylation and conjugation. Chenodeoxycholic acid (CDCA) and cholic acid (CA) are primary BAs synthesized from cholesterol and conjugated with taurine or glycine in the liver; in the colon, bacteria deconjugate and dehydroxylate the BAs to form, respectively, lithocholic acid and deoxycholic acid (DCA). 2 Taurine or glycine conjugation of the BAs permits the ionization of BAs which increases their solubility and their impermeability to cell membranes, allowing BAs to reach the critical micellar concentration for spontaneous formation of micelles. In the micelles, the polar BAs surround the insoluble, hydrophobic fatty acids and monoglycerides and present the hydrophobic fat molecules to the enterocyte brush border membrane of the small intestine for digestion and absorption.
The apical Na + -dependent bile salt transporter (ASBT) (also called ileal BA transporter or SLC10A2 [solute carrier family 10, member two]) is responsible for the active reuptake of BAs in the terminal ileum. This reabsorbs approximately 95% of BAs in the terminal ileum and results in a functional enterohepatic circulation of BA, 3 transporting the BAs back to the liver. Several molecular mechanisms are involved in the enterohepatic circulation: farnesoid X receptor (FXR) is expressed in ileal enterocytes and hepatocytes; BAs are agonists of the FXR; sensing of the enterocyte BA pool by FXR affects the liver by way of the endocrine factor, fibroblast growth factor 19 (FGF-19); FGF-19 is released from enterocytes into the portal circulation and activates FGF receptor 4 (FGF-R4) in hepatocytes in a process that involves interaction with klothob on the hepatocyte membrane, resulting in downregulation of cholesterol 7a-hydroxylase (CYP7A1) and therefore inhibition of the BA synthesis. Cholerheic or BA diarrhea is thought to result predominantly from the interruption of the enterohepatic circulation. 3 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CLASSIFICATION OF BILE ACID MALABSORPTION/ DIARRHEAS
The causes of BA diarrhea (BAD) are based on the original classification of BA malabsorption (BAM):
Type 1: Ileal dysfunction and impaired reabsorption, e.g., Crohn's disease Type 2: Primary, or idiopathic, BAD produces a similar picture of increased fecal BAs, watery diarrhea, and response to BA sequestrants in the absence of ileal or other obvious gastrointestinal disease Type 3: Other gastrointestinal disorders which affect absorption, such as small intestinal bacterial overgrowth, celiac disease, or chronic pancreatitis A fourth category of BAD may result from excessive hepatic BA synthesis; for example, the oral hypoglycemic drug, metformin, is associated with increased hepatic BA synthesis. 2. Genetic mutations in the apical sodium-bile acid transporter
Genetic mutations in the apical sodium-bile acid transporter (ASBT) are extremely rare. 12, 13 In addition, defective BA uptake into ileal mucosal biopsies was excluded by Bajor et al. 14 3. Accelerated small bowel transit bypassing active bile acid transport in the ileum Accelerated small bowel transit bypassing active BA transport in the ileum has been hypothesized as a cause of BAM in idiopathic 15 and postradiation cases. 16, 17 While this is theoretically possible, it seems unlikely given the ASBT's affinity for BA, and it is unclear whether the accelerated small bowel transit is a cause or an effect of the BAM. 
drome (IBS-D)
. 18 Pharmacogenetic studies of the influence of KLB (rs17618244) on the dose-response effects of administered chenodeoxycholate on the emptying rate of the ascending colon 11 suggest that KLB variation may influence colonic response to BAM, and exome DNA sequencing studies showed KLB (rs1015450, downstream) association with fecal BAs and FGF-R4 (rs1966265, nonsynonymous) with colonic transit. 19 5. Upregulation of the membrane bound bile acid receptor, TGR5 or GPBAR1
TGR5, or GPBAR1, is a member of the G protein-coupled receptor superfamily that functions as a cell surface receptor for BA, 20 including colonic epithelial cells, 21 regulating basal and cholinergic-induced secretion in rat colon 22 and colonic transit. 23 We have recently shown that genetic variation in GPBAR1
predisposes to quantitative changes in colonic transit and BA excretion.
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CELLULAR MECHANISMS OF BILE ACID DIARRHEA
BA chemistry determines effects on colonic mucosa; in general, the surface active properties that lead to increased colonic mucosal permeability and electrolyte and water secretion are associated with two hydroxyl groups at the 3,7 (CDCA) or 3,12 (DCA) positions in the a-configuration. BAs regulate many cell types in the gut wall and beyond by activating nuclear and plasma membrane receptors. Of these, the G protein-coupled receptor, TGR5, has emerged as a key mediator of the nongenomic actions of BAs. TGR5 is a cell-surface receptor that couples to Gas, formation of cAMP, activation of protein kinase A and extracellular signal-regulated kinases, and inhibition of inflammatory signaling pathways. 25 The mechanisms of diarrhea include increased mucosal permeability; 26 10, 38 In fact, the IBS-D patients had evidence of increased fecal BA excretion and increased hepatic BA synthesis. It has been estimated that 1% of the population of Western countries suffers from BAD. 39 
INTERACTIONS OF THE MICROBIOME OF THE COLON AND BILE ACIDS
The colonic microbiome is responsible for the dehydroxylation of cholic and chenodeoxycholic acids to the secondary BAs, deoxycholic and lithocholic acids. Gut microbiota also regulate expression of fibroblast growth factor 15 in the mouse ileum and cholesterol CYP7A1 in the liver by FXR-dependent mechanisms. 40 The microbiome influences the generation of BAs and other organic acids in the murine colon. 41 In humans, BA pool size and composition appear to be major regulators of microbiome structure, which, in turn, appears to be an important regulator of BA pool size and composition. 42 Ongoing research seeks to unravel the contributions of the microbiome and BA composition to diverse conditions including colorectal cancer, 43 inflammatory bowel disease, 44 and irritable bowel syndrome. 45 
CHANGES IN THE PROFILE OF FECAL BILE ACIDS IN IR-RITABLE BOWEL SYNDROME
Several studies have now reported the profile of fecal BAs in patients with IBS-D. Duboc et al. 45 reported that the percentage of fecal primary BA was significantly higher in IBS-D patients than in healthy controls, and it was significantly correlated with stool consistency and frequency. They also reported a significant increase of Escherichia coli and a significant decrease of leptum and bifidobacterium in IBS-D patients. Shin et al. 38 confirmed that fecal levels of primary BAs (cholic and chenodeoxycholic [CDCA] acids) were higher in 31 subjects with IBS-D, compared with 30 healthy controls, and also reported that the proportions of fecal secretory BAs (chenodeoxycholic and deoxycholic [DCA] acids) were lower in 30 IBS-C patients compared with controls. An extension study of the latter cohort involving 64 patients with IBS-D confirmed the differences in the proportions of primary and secondary BAs in feces of patients with IBS-D. In addition, the phenotypes of patients with IBS-D and increased total fecal excretion of >2,337 μmol per 48 hours differed from that of IBS-D patients with normal fecal BA excretion, including higher body mass index, increased fecal fat excretion, higher proportion of primary BAs (CA and CDCA) in stool, and a trend to faster colonic transit. 46 SeHCAT; retention of the isotope in the body at 7 days is measured noninvasively by whole body gamma counter and expressed as a percentage of administered dose. BA may undergo five enterohepatic circulations per day with ~5% loss in the stool with each circulation; retention rates of 5%, 10%, and 15% are used to estimate the relative severity of BAM.
DIAGNOSIS OF BILE ACID MALABSORPTION
Serum 7 a-hydroxy-4-cholesten-3-one (C4) measures BA synthesis, 90% of which is regulated by the rate-limiting enzyme, cholesterol CYP7A1. C4 is a downstream product of CY- P7A1. Serum C4 is a simple blood test, but it requires standardized specimen collection time because of diurnal variability. 51 Accurate method for measurement uses liquid chromatographytandem mass spectrometry. 52 The clinical performance of the C4 assay demonstrated a sensitivity of 90%, specificity of 79%, negative predictive value of 98%, and positive predictive value of 74% when compared to the 75 SeHCAT test. The high negative predictive value makes the assay attractive as a screening test to rule out BAM. 53 C4 was unrelated to age, gender or serum cholesterol when analyzed against potential covariates. 53 When compared to elevated 48-hour fecal BA excretion, elevated serum C4 did not identify phenotype differences (such as increased fecal fat and colonic transit) among patients with IBS-D, other than documenting the increased fecal BAs among those with elevated serum C4, defined as >47.1 ng/mL. 46 In summary, serum C4 test is applicable to a majority of patients, but requires further clinical validation including responsiveness to BA sequestrants therapy or FXR agonists in patients with BAM. Fecal measurements to quantify total and individual fecal BAs are technically cumbersome and not widely available. 10, 38, 46 These Mayo Clinic studies showed that IBS-D is associated with higher serum C4, higher total fecal BA, and increased secretory BAs (e.g., CDCA, DCA). In addition, high fecal BA excretion was associated with a more significant IBS-D phenotype, characterized by higher fecal fat and a trend toward accelerated colonic transit. 46 Indeed, fecal BA excretion and colonic transit were validated as biomarkers that identified mechanisms that could be targets of treatment in patients with IBS-D. 54 Excretion of >2,337 μmol per 48 hours (upper limit of normal) is used as an index of BAM. 46, 54 An enzymatic 3a-steroid dehydrogenase assay indirectly measures fecal BA. 3a-Steroid dehydrogenase is used to oxidize deconjugated BAs and produces NADH, which is then measured biochemically. This method requires proper stereotactic alignment of enzyme and substrate and with a variety of conjugations (sulfonation, glucuronidation) of BAs while they are in the small intestine. This method would lack precision if it was used to measure concentrations of BAs in small bowel fluid or ileostomy effluent. In addition, because it does not assess BAs with hydroxyl groups in the b-configuration, it tends to underestimate total BAs.
Indirect measurements of bile acids
Serum FGF-19 is a useful screening test for BAD, 39 given the inverse relationship between C4 and FGF-19 originally described by Walters et al. 9 It has been validated in studies using 75 SeHCAT retention as the gold standard 55 and by comparisons with serum C4. 56 In the study of Pattni et al. 56 of 258 patients, sensitivity and specificity of FGF 19 at 145 pg/mL for detecting a C4 level >28 ng/mL were 58% and 79%, respectively, and for C4 >60 ng/mL (denoting high BA synthesis), the sensitivity and specificity of FGF-19 were 74% and 72%, respectively. 55 The 63 emptying of the ascending colon took an average of 4 hours longer in patients given colesevelam (1.875 g, twice a day) compared with placebo, treatment effect was significantly associated with baseline serum C4 levels, and colesevelam caused greater ease of stool passage and somewhat firmer stool consistency.
In an unpublished open-label study (Camilleri 2014, unpublished) of the same dose of colesevelam in 12 IBS-D patients with elevated fecal BA excretion, we have also shown that colesevelam sequestered BAs and resulted in significantly firmer stool consistency.
Experimental agents inhibiting bile acid diarrhea by cellular mechanisms
FGF-19 production is stimulated by the FXR agonist, obeticholic acid, 64 which may potentially reverse the FGF-19 deficiency postulated in BAM that leads to excessive hepatocyte BA synthesis. This treatment has been associated with improved stool frequency and consistency in a preliminary study of patients with BAD. 65 Another FXR agonist, GW4064, attenuated Cl − secretory responses to both Ca 2+ and cAMP-dependent agonists, and may be efficacious in the treatment of BAD through antisecretory actions on the colonic epithelium. 66 
CONCLUSION AND FUTURE DIRECTION
The pioneering work conducted 40 years ago by giants in this field (Drs. Alan Hofmann, Donald Small, Hans Fromm, and Vinton Chadwick) is finally going to have an impact beyond the patients with ileal resection or ileal Crohn's disease. BA diarrhea is finally appreciated as a significant cause of functional, otherwise unexplained, chronic diarrhea in about one-third of such patients. The availability of simple diagnostic stool tests (fecal BA excretion performed at the time of fecal fat measurement) and, even more applicable, serum or urine tests will enhance the ability of physicians to diagnose this eminently treatable disorder.
In the future, BA sequestration with tablet formulations that are associated with higher compliance or Farnesoid X receptor agonists will impact the care of patients and likely reduce overall healthcare costs by reducing the need for expensive tests like colonoscopy and biopsies or treatments like biologic agents in patients with Crohn's disease.
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